Ivermectin as a Novel Therapy in COVID-19 Treatment

The Efficacy of Ivermectin in COVID-19 Treatment

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04403555

Enrollment

164

Registered

2020-05-27

Start date

2020-06-01

Completion date

2020-12-01

Last updated

2021-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID

Brief summary

Efficacy of Ivermectin in COVID-19 treatment

Detailed description

Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 treatment

Interventions

DRUGIvermectin

Ivermectin treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR.

Exclusion criteria

* Allergy or contraindication to the drugs used in the study. * Pregnant and lactating mothers. * Patients with cardiac problems.

Design outcomes

Primary

Measure	Time frame	Description
The number of patients with mortality	1 month	Improvement of survival

Secondary

Measure	Time frame	Description
Length of hospital stay	1 month	Effect on the length of hospital stay
The need for mechanical ventilation	1 month	Need for mechanical ventilation

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026